- February 10, 2012
- 08:45 AM CET
- search
- T&C's
- Disclaimer
- PRIVACY POLICY
- Imprint
- RSS
- ©2012 EVOTEC
Evotec - Research never stops
- Loading...
Archive
Dec 14, 2009
Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd.
Nov 10, 2009
Evotec to Voluntarily Delist from NASDAQ
Oct 22, 2009
Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim
Oct 20, 2009
Evotec Signs Agreement with DiscoveRx Corporation to Support High Throughput Screening Services
Oct 15, 2009
Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd.
Oct 01, 2009
Evotec achieves milestone with Cardioxyl Pharmaceuticals - as compound enters the clinic
Sep 08, 2009
Evotec starts Phase I with EVT 103, an NR2B-selective NMDA receptor antagonist
Aug 31, 2009
Evotec completes acquisition of controlling majority stake in Research Support International Private Limited (RSIPL)
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that the acquisition of the controlling majority stake of Research Support International Private Limited ("RSIPL") has been successfully completed and that RSIPL is a 70%, majority owned subsidiary of Evotec as of August 31, 2009.
- read more
Aug 06, 2009
Evotec Accelerates Growth Strategy of its Discovery Alliance Business with Acquisition of Indian RSIPL
Jul 21, 2009
Evotec Signs High Throughput Screening Collaboration with Alios Biopharma, Inc
Jul 14, 2009
Evotec announces Research Agreement on Fragment- Based Drug Discovery with Cubist Pharmaceuticals
Jun 29, 2009
Evotec Announces the Successful Completion of the First Phase I Study with EVT 401, an Oral P2X7 Receptor Antagonist - Very Good Safety Profile and Confirmed "On Target Activity"
Apr 27, 2009
Walter Wenninger Nominated for Election as New Supervisory Board Member of Evotec
Mar 27, 2009